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Abstract
Background: Identification of neoplastic cells in cere-
brospinal fluid (CSF) by cytological analysis is the key
diagnostic feature of leptomeningeal metastasis (LM).
Because of the lack of sensitivity of this test, consid-
erable efforts have been made to identify alternative
diagnostic markers. Data from the literature suggest
that measurement of tumor markers (TM) in CSF may
be helpful for improving the diagnosis.
Methods: We analyzed the concentrations of the TM
carcinoembryonic antigen (CEA), CA15.3, CA125 and
CA19.9 in both CSF and serum from 18 patients with
neoplastic meningitis diagnosed by CSF cytology. We
also performed these same measurements in 50
patients affected by other neurological diseases
(OND) in order to evaluate putative intrathecal syn-
thesis. In addition, CSF and serum concentrations of
the proangiogenic factor VEGF (vascular endothelial
growth factor) were evaluated.
Results: All LM patients showed intrathecal synthesis
for at least one TM. In one patient, a negative CSF
cytology after treatment paralleled normalization of
tumor marker synthesis. None of the OND patients
displayed intrathecal TM synthesis. The VEGF Index
(CSF/serum VEGF relative to CSF/serum albumin
ratios) was significantly higher in LM patients com-
pared with the control group. However, significant
overlap between LM patients and values seen in
those with OND was observed.
Conclusions: Evaluation of intrathecal TM synthesis is
a specific, sensitive, reliable, and reproducible diag-
nostic tool, and is useful to support diagnosis of car-
cinomatous meningitis.
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Introduction
Leptomeningeal metastasis (LM) is a complication
occurring in oncological patients when tumor cells
spread into the subarachnoid space and cerebrospinal
fluid (CSF) compartment. According to autopsy stud-
ies, LM occurs in 5%–8% of cancer cases. However,
the incidence is increasing and is probably due to
more effective therapies and better diagnostic tools
(1, 2). Although LM is a late complication in most
patients, in 5%–10% it is the first manifestation of can-
cer (3). Prognosis is generally poor, with a mean sur-
vival time of 3.5–6 months (4). However, some
patients survive longer than 12 months, particularly
those with breast cancer (5). Early diagnosis is crucial
to begin aggressive therapy and to prevent progres-
sive neurological deterioration.
The ‘‘gold standard’’ for the diagnosis of LM is
positive CSF cytological analysis for tumor cells.
Unfortunately, this test has low-sensitivity, 50%–60%
at initial lumbar puncture, which can be improved to
80% with repeated sampling of CSF (6, 7).
The tumor markers (TM) carcinoembryonic antigen
(CEA), CA15.3, CA125 and CA19.9 are glycoproteins
expressed on various cell types, but produced in high-
er concentrations by cancer cells. Higher TM levels in
serum are not considered specific for malignancies,
since they may be increased in some benign condi-
tions (8, 9). Guidelines suggest that measurement of
TM in serum is not an adequate screening tool, with
the exception of CA125 which is recommended for the
diagnosis of ovarian cancer in women at high risk for
the disease. However, TM play an important role in
the monitoring of patients undergoing treatment
(10, 11).
In physiological conditions within the CNS, no cells
are able to produce TM. Increased concentrations of
CEA (12, 13), a-fetoprotein and b-human chorionic
gonadotropin (bHCG) (14) have been observed in the
CSF of patients with LM, but the amount of TM in CSF
due to filtration and/or to dysfunction of the blood/
CSF barrier was not always evaluated correctly (15).
In most cases, TM levels have been considered
diagnostic for LM when concentrations in CSF were
greater than those observed in serum (16).
In the present work, we evaluated intrathecal syn-
thesis of CEA, CA15.3, CA125 and CA19.9 in 18 car-
cinoma patients with LM diagnosed by positive CSF
cytology, and in 50 patients with other neurological
diseases (OND). Intrathecal synthesis was calculated
according to the mathematical approach suggested
by Reiber for immunoglobulins (17, 18).
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Table 1 Demographics of LM patients.
Patients Primary tumor Time from Cerebral Age Gender
diagnosis, years metastasis
Patient 1 Small-cell lung cancer 0–3 – 55 M
Patient 2 Breast carcinoma )3 – 55 F
Patient 3 Small-cell lung cancer 0–3 – 50 F
Patient 4 Small-cell lung cancer – Yes 46 M
Patient 5 Cervix carcinoma 0–3 – 42 F
Patient 6 Breast carcinoma )3 – 45 F
Patient 7 Small-cell lung cancer 0–3 – 59 F
Patient 8 Breast carcinoma )3 – 63 F
Patient 9 Breast carcinoma )3 – 46 F
Patient 10 Breast carcinoma )3 – 51 F
Patient 11 Breast carcinoma – – 52 F
Patient 12 Breast carcinoma – – 67 F
Patient 13 Breast carcinoma )3 – 56 F
Patient 14 Colon carcinoma 0–3 Yes 67 M
Patient 15 Breast carcinoma )3 Yes 36 F
Patient 16 Gastric carcinoma )3 – 61 F
Patient 17 Breast carcinoma )3 – 68 F
Patient 18 Breast carcinoma 0–3 – 55 F
Data refer to time of diagnosis of LM. In patient 4, patient 11 and patient 12, LM was the first manifestation of systemic
cancer.
Vascular endothelial growth factor (VEGF) is a
proangiogenic factor and a vascular permeability fac-
tor, playing a critical role in tumor angiogenesis (19).
An increase in VEGF plasma concentrations was
described in patients with different solid tumors. It
has been reported that VEGF could be a useful bio-
logical marker for detection of carcinomatous men-
ingitis (20, 21).
In the same 18 LM patients and in a subgroup of 26
OND patients, VEGF concentrations were measured in
serum and CSF. We performed these measurements
in order to evaluate if the VEGF Index may provide
additional information about diagnosis and/or prog-
nosis in suspected LM.
Materials and methods
Patients
Eighteen patients with positive CSF cytology for LM were
investigated. The demographics of the patients are reported
in Table 1. A systemic tumor had already been diagnosed in
15 patients, nine of which were diagnosed more than 3 years
before LM. In three patients (patients 4, 12 and 16), neuro-
logical symptoms due to LM were the first clinical manifes-
tations of cancer. In patient 13, a definitive diagnosis of LM
was possible following a second lumbar puncture.
To evaluate the specificity of intrathecal synthesis of TM,
50 patients with non-malignant neurological diseases (OND)
were included in the study as the control group (24M, 26F,
mean age 51, range 19–74). OND patients were affected by
inflammatory (ns33) or neurodegenerative diseases (ns17).
CSF and blood samples were collected by lumbar puncture
and by venous puncture, respectively.
Examination of CSF included cell count, glucose, total
protein and albumin quotient (QAlbsCSF albumin/serum
albumin=1000). The latter parameter is recommended to
evaluate function of the blood/CSF barrier. All CSF para-
meters were analyzed within 2 h of collection. Cytospin for
cytological analysis was also performed within 2 h.
For quantitation of TM and VEGF, sera and cell-free CSF
were aliquoted, stored at –808C and analyzed within 3
months.
Cytological examination was performed for both LM and
OND patients.
Biochemical analysis
Serum and CSF CEA, CA15.3, CA125 and CA19.9 concentra-
tions were evaluated using Modular Analytics SWA (Roche
Diagnostics GmbH, Mannheim, Germany). The lower limit
of detection for CEA, CA15.3, CA125 and CA19.9 was 0.2
ng/mL, 1 UI/mL, 0.6 UI/mL, and 0.6 UI/mL, respectively. The
lower limit of detection was validated using 20 CSF samples
from OND patients with normal biochemical parameters.
VEGF concentrations were measured in both serum and
CSF in all patients with LM, and in a subgroup of 26 patients
(18 patients showing CFS/blood barrier dysfunction, i.e.,
QAlb)8, 10 F, 8 M, 12 inflammatory diseases and 6 neuro-
degenerative; 8 patients with QAlb-8, 5 F, 3 M, 6 inflam-
matory diseases and 2 neurodegenerative). VEGF concentra-
tions were measured using a commercially available ELISA
assay with a detection limit of -5 pg/mL (R&D Systems,
Minneapolis, MN, USA).
Intrathecal TM synthesis
Intrathecal synthesis was calculated using a mathematical
approach that identifies the amount of tumor markers detect-
ed in CSF due to filtration from blood and/or barrier dys-
function (17). For intrathecal TM synthesis, was applied the
Reiber’s formula for evaluation of intrathecal IgA synthesis,
since the molecular weight of the analytes (i.e., CEA: 200
kDa, CA125: 500 kDa, CA15.3: 300–450 kDa, CA19.9: 360 kDa)
(22) is similar to that of IgA (18).
TM Intrathecal synthesis (TMIS) was assessed as follows:
TM swQ –Q (TM)x=TM /1000IS Tm Lim serum
(Q sTM /TM =1000)Tm CSF Serum
2 2yQ (TM)sa/b QA1b qb –cLim
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Table 2 CSF values for glucose (reference range: 40–80
mg/dL), QAlb (CSF/serum albumin ratio), cell count and
tumor cells, evaluated in cytological analysis, in LM patients.
Patients CSF glucose, QAlb Total Tumor
mg/dL cells/mL cells/mL
Patient 1 85 20.32 8 3
Patient 2 41 25.4 8.3 0.6
Patient 3 -2 21.1 31 22
Patient 4 44 13.4 23 1
Patient 5 -2 19.6 85 25
Patient 6 67 215.8 13 2
Patient 7 32 43.9 34 10
Patient 8 29 21.7 94 3
Patient 9 11 28.5 35 6
Patient 10 51 135.9 8.6 1
Patient 11 39 25.2 13 5
Patient 12 53 76.9 3 0.6
Patient 13 32 34.11 12 0
Patient 14 40 16.4 4.3 0.3
Patient 15 53 63.1 12 0.6
Patient 16 11 10.8 40 20
Patient 17 30 27.3 25 1
Patient 18 41 9.82 34 30
Data for patient 13 refer to the first lumbar puncture which
was negative for tumor cells. Conversion factor glucose
(mg/dL)=0.0555sglucose (mmol/L).
2 –6 3yy(Q (TM)s0.77 QAlb q23=10 –3.1=10 )Lim
QLim is the upper discrimination limit of the reference
range, indicating no synthesis in the Reiber graphs.
The parameters a/bs0.77, b2s23=10–6 and cs3.1=10–3
are referred to IgA and depend only on the molecular weight.
When the TM concentration in CSF due to intrathecal pro-
duction was )10% as compared to QLim (cut-off)10%),
samples were considered positive for intrathecal synthesis.
The VEGF Index was calculated as follows:
VEGF Indexs(VEGF /VEGF )/(ALB /ALB )CSF serum CSF serum
Statistical analysis
Statistical analysis of VEGF Index was performed using the
Mann-Whitney test and x2 test. The level of significance was
set at 0.05.
Results
All LM patients showed blood/CSF barrier dysfunc-
tion (QAlb)8). Nine of 18 patients (50%) showed
decreased glucose concentrations in CSF (reference
range: 40–80 mg/dL), 17 of 18 (94%) displayed mild
pleiocytosis (Table 2). Intrathecal synthesis for at least
one TM was detected in all LM patients that were
evaluated (Table 3A), while none of the OND patients
displayed TM production in CSF.
Intrathecal synthesis of CEA was observed in 17 of
18 patients (percentage of CEA of intrathecal produc-
tion, range: 92%–100%), CA125 in nine of 18 (range:
38%–100%), CA15.3 in 15 of 18 (range: 53%–100%)
and CA19.9 in 12 of 18 (range: 51%–100%). In addi-
tion, 16 of 18 patients were positive for two or more
TM, 13 of 18 were positive for three or more markers
and six of 18 were positive for all TM.
CSF TM concentrations were measurable in two
OND patients (OND patient 1: CSF CA19.9: 1.62 UI/mL,
serum CA19.9: 33.2 UI/mL, QAlb: 129; and OND
patient 2: CSF CA125: 1.16 UI/mL, serum CA125:
91.7 UI/mL, QAlb 21). However, no intrathecal synthe-
sis was detectable (OND patient 1: CA19.9ISs–0.76,
and OND patient 2: CA125ISs–0.84, -Qlim). This sug-
gests that the increase in TM CSF concentration
observed in these patients was due to both high
serum concentrations and/or to dysfunction of the
CSF/blood barrier.
No correlation was found between TM and tumor
type. As a matter of fact, patient 13, diagnosed with
breast carcinoma, did not show intrathecal synthesis
of CA15.3, which is more frequently associated with
breast cancer. Also, patient 5, diagnosed with uterine
carcinoma, showed CSF CA19.9 values higher than
CA125, which is closely related to ovarian carcinoma.
Patient 13, with a negative cytological examination
at the initial lumbar puncture had intrathecal synthe-
sis for CEA, CA125 and CA19.9. A second lumbar
puncture performed on this patient revealed positive
cytology, confirming the diagnosis of LM.
Only four patients were monitored for intrathecal
synthesis of TM at different time points. These
patients were monitored during intrathecal treatment
with methotrexate and/or liposomal cytosine-arabi-
noside ARA-C (Depocyte). Three patients showed
only slight fluctuations in TM (data not shown). How-
ever, patient 10, following 6 months of therapy (first
with intrathecal methotrexate, 15 mg, and then with
Depocyte, 50 mg), showed negative CSF cytology
which paralleled the absence of intrathecal synthesis
of CEA and CA15.3. After more than 2 years, the
patient remains clinically stable. Serum concentra-
tions of CEA, CA15.3, CA125 and CA19.9, are reported
in Table 3B.
With respect to the VEGF Index, no significant dif-
ferences were observed between the two groups of
OND patients (i.e., OND with QAlb)8, mean: 4.7,
range 0–24.4; OND QAlb-8, mean: 4.5, range 1.1–16).
Thus, OND patients were then analyzed as a single
group which showed a mean of 4.6 (range 0–24.4).
The VEGF Index was significantly increased in LM
patients as compared to OND patients (mean LM:
117.3, range 4.05–628; p-0.001) (Table 3A).
Setting the VEGF Index cut-off value at 10 revealed
a sensitivity of 83.3% and specificity of 88.4%. A sta-
tistically significant difference was detected between
LM and OND patients (p-0.025, x2 test).
The significant overlap between LM and OND
patient values underlines the lower diagnostic speci-
ficity of this test when compared to cytological exam-
ination or intrathecal TM synthesis.
Discussion
The search for additional laboratory tests improving
the diagnosis of LM is an important issue for CSF
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Table 3A TM intrathecal synthesis and VEGF Index in LM patients.
Patients CEA CA125 CA15.3 CA19.9 VEGF
ng/mL % IU/mL % IU/mL % IU/mL %
Index
Patient 1 7.83 98 n.d. 0 6.05 74 2.63 91 7.81
Patient 2 0.3 68 0.6 38 2.02 87 0.58 83 120.92
Patient 3 0.93 89 n.d. 0 2.53 88 0.62 68 207
Patient 4 11.27 100 n.d. 0 n.d. 0 2786.1 100 4.05
Patient 5 12.63 99 2513.3 99 17.32 98 10203.8 100 396
Patient 6 115.0 96 34.4 96 209.6 70 0 0 11.42
Patient 7 181.9 99 26.5 98 0.9 75 14.75 98 28.85
Patient 8 1.87 99 n.d. 0 57.7 97 0.87 51 81.09
Patient 9 6.31 99 1.38 79 14.71 95 1135.5 100 141.58
Patient 10 0.75 86 n.d. 0 1.3 45 n.d. 0 6.48
Patient 11 n.d. 0 n.d. 0 30.46 89 n.d. 0 22.14
Patient 12 1.85 93 n.d. 0 72.29 96 0 0 43.87
Patient 13 34.14 100 2.43 71 n.d. 0 1.02 84 13.29
Patient 14 536 100 n.d. 0 n.d. 0 n.d. 0 628.04
Patient 15 31.6 92 13.3 89 1.33 53 5.4 79 18.52
Patient 16 48.75 100 1217.5 100 5.47 98 999 100 99.4
Patient 17 253.9 100 n.d. 0 4.7 94 244.4 100 184.8
Patient 18 2.04 100 12.6 99 27.8 100 n.d. 0 95.41
TMIS, calculated according to Reiber’s formula, is reported as both concentration and percentage (cut-off: )10%). CEA was
positive in 17/18, CA125 in 9/18, CA15.3 in 15/18, CA19.9 in 12/18 patients. The VEGF Index was significantly increased in LM
patients as compared to OND patients (mean LM: 117.3 vs. mean OND: 4.6, p-0.001). n.d., not detectable; 0, no intrathecal
synthesis but detectable CSF amounts, due to high QAlb or high TM concentration in serum.
Table 3B Serum concentration of TM in LM patients.
Patients CEA, CA125, CA15.3, CA19.9,
ng/mL IU/mL IU/mL IU/mL
Patient 1 14.9 54.04 160.8 20.16
Patient 2 7.24 56.74 18.1 7.28
Patient 3 8.01 10.09 25.14 22.46
Patient 4 3.39 10.55 22.73 364.4
Patient 5 4.86 1256 22.57 2572
Patient 6 42.61 42.55 393 19.87
Patient 7 35.7 17.69 9.69 9.46
Patient 8 2.78 7.29 124.1 17.71
Patient 9 4.2 18.9 41.18 234.8
Patient 10 1.2 8.6 16.3 6.3
Patient 11 2.13 15.4 246.8 14.24
Patient 12 2.66 20.5 58.85 57.69
Patient 13 6.47 41.4 8.29 8.24
Patient 14 123.5 12.3 19.87 9.24
Patient 15 41.3 17.4 36.4 25.7
Patient 16 7.62 86.2 20.42 169.5
Patient 17 3.7 12.2 18 29.65
Patient 18 2.48 26 32 10
Reference range: CEA, 0–10 ng/mL; CA125, 0–35 IU/mL;
CA15.3, 0–31.3 IU/mL; CA19.9, 0–37 IU/mL.
analysis. A number of different biological markers
such as lactate dehydrogenase (LDH) and b-glucuro-
nidase have been proposed (2). However, the lack of
sensitivity and specificity of these analytes limits their
use in diagnostic practice.
Applying the mathematical approach suggested by
Reiber (17, 18) we evaluated the sensitivity and the
specificity of intrathecal synthesis of CEA, CA125,
CA15.3 and CA19.9 in 18 patients with diagnosed LM
from solid cancers, and in a control group. We com-
pared sensitivity and specificity of intrathecal synthe-
sis of TM for LM detection with those of VEGF Index.
Our data show that intrathecal synthesis of TM is
100% specific for LM. In fact, no OND patients dis-
played TM synthesis in the CSF compartment, where-
as all LM patients were positive. In addition, TMIS
proved to be as sensitive as cytological examination.
Also, we measured TM using with an automated ana-
lyzer (i.e., Modular Analytics SWA, Roche), but better
results could be obtained using methods with a lower
detection limit, such as ELISA.
We found intrathecal release of TM in all LM
patients studied. There was no clear correlation with
the type of carcinoma. Since CEA was detected in
almost all patients (17/18), this should be considered
the marker of choice as a diagnostic test for LM.
Quantitation of CA125, CA15.3 and CA19.9 may be
performed only in those cases with negative intra-
thecal synthesis of CEA.
According to some authors, CSF analysis of TM
such as CEA, bHCG or a-fetoprotein can occasionally
be useful in diagnosis of LM when CSF concentrations
are above a pre-determined cut-off value (15), or
when CSF values are higher than serum values (16),
in the absence of dysfunction of the blood/CSF bar-
rier, or when TM are disproportionately increased in
the CSF (23).
The concentration of a specific protein in CSF is
dependent on its concentration in blood and on CSF/
blood barrier integrity. Protein entry from blood into
the CSF follows the laws of diffusion as a function of
molecular size. Thus, the choice of a pre-determined
cut-off value in CSF is inadequate (i.e., CEA-4 mg/L;
15). In addition, since a higher concentration in CSF
compared to serum in at least one TM was present in
11 out of 18 patients with LM, use of the above-men-
tioned approaches to define abnormal CSF levels of
the markers would significantly decrease the test sen-
sitivity. Since alterations in blood/CSF barrier function
are found in ;80% of LM patients (2), the correct
approach should consider all these variables. Our
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data further suggest that the well-known hyperbolic
function of Reiber graphs (17, 18) could be applied to
TM, and intrathecal synthesis of TM may be an effec-
tive diagnostic tool.
In addition to laboratory tests, neuroradiological
techniques, especially gadolinium-enhanced magnet-
ic resonance imaging (MRI) which is more sensitive
than computed tomography (CT), can be important
diagnostic tools.
Although neuroradiological findings may be asso-
ciated with other non-neoplastic diseases, they are
often highly suggestive for LM diagnosis in an appro-
priate clinical context.
Concerning the relationship between TM concentra-
tions and disease course, correlation between TM
concentrations and disease progression was previ-
ously reported by Kosmas and co-workers (24, 25).
These investigators monitored CEA, CA15.3, CA125
and CA19.9 concentrations in serum and CSF of five
breast cancer patients with carcinomatousmeningitis.
In our study, only four LM patients were monitored
over time. Interestingly, patient 10, who showed mild
intrathecal synthesis of two markers when diagnosed
for LM, displayed negative cytology and no intrathe-
cal synthesis of TM after 6 months of intrathecal treat-
ment with ARA-C. This patient remains clinically
stable 2 years after diagnosis of LM. However, this
single finding does not allow any conclusion to be
made about the potential prognostic value of TM.
Also, the VEGF Index was significantly higher in LM
patients compared with controls. However, produc-
tion of VEGF in the CSF compartment was observed
in most of the OND patients, although at lower levels.
It should be noted that VEGF may increase in infec-
tious meningitis (26, 27) and in other inflammatory
conditions (28). In our study, the VEGF Index per se
did not increase diagnostic information, since both its
specificity and sensitivity were lower than those of
TMs. Further studies are needed to investigate the
possible use of the VEGF Index for the detection of
LM dissemination of solid tumors such as melanoma
or glioma.
Other authors have previously suggested a mathe-
matical model for discriminating LM from non-LM
patients measuring VEGF, tissue plasminogen acti-
vator (tPA) and transforming growth factor-b (TGF-b)
concentrations in CSF and serum (28). However, this
intriguing approach seems too difficult to apply in the
diagnostic routine.
The paucity and fragility of tumor cells in the CSF
is the main cause of low-sensitivity of cytological
examination. It is well known that delayed processing
of samples may increase the incidence of false-neg-
ative cytology (29). CSF for cytological examination
should be processed within 2 h, while TM are stable
for at least 5 days at 28C–88C, and for months if stored
at –208C according to the manufacturer’s instruction
and our own experience. Quantitation of glycopro-
teins such as CEA, CA15.3, CA125 and CA19.9 that are
more stable than cells can be particularly helpful. In
addition, quantitation is possible even in mishandled
samples (i.e., delay in CSF processing).
The experience of the cytopathologist is another
important aspect for the correct diagnosis of LM. For
this reason, only some hospitals can afford this kind
of analysis. On the contrary, TM measurements
require equipment that is often available in most
laboratories.
Our observations, obtained on 18 patients with LM
should be considered preliminary. Further studies,
currently in progress with a larger cohort of patients,
are needed to confirm these findings and to assess
their prognostic values. However, intrathecal synthe-
sis of TM, calculated according to Reiber formula, is
a specific and sensitive parameter. This parameter
can be obtained using reproducible and standardized
methods, and can be used in laboratories for clinical
investigation.
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